NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
Journal: Journal Of The National Comprehensive Cancer Network : JNCCN
Published:
Abstract
The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell-engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
Authors
John Thompson, Bryan Schneider, Julie Brahmer, Mohammad Zaid, Amaka Achufusi, Philippe Armand, Meghan Berkenstock, Bonnie Bermas, Tawnie Braaten, Lihua Budde, Saurin Chokshi, Zachary Crees, Marianne Davies, Changchun Deng, Yaron Gesthalter, Michael Jain, Prantesh Jain, Andrew Jallouk, Benjamin Kaffenberger, Maya Khalil, Melissa Lechner, Tianhong Li, Alissa Marr, Suzanne Mcgettigan, Jordan Mcpherson, Theresa Medina, Nisha Mohindra, Anthony Olszanski, Olalekan Oluwole, Sandip Patel, Jason Prosek, Sunil Reddy, Pankti Reid, John Ryan, Mabel Ryder, Huda Salman, Bianca Santomasso, Scott Shofer, Jeffrey Sosman, Yinghong Wang, Vlad Zaha, Stephen Zucker, Megan Lyons, Ajibola Awotiwon, Lisa Hang